Abstract
A substantial proportion of patients with rheumatoid arthritis do not respond to tumor necrosis factor blocking therapy. Results of a large genome-wide association study demonstrate evidence of novel genetic factors that determine response to treatment, which could provide a basis for individualizing therapy.
MeSH terms
-
Adaptor Proteins, Signal Transducing / genetics
-
Arthritis, Rheumatoid / drug therapy*
-
Cell Adhesion Molecules
-
Humans
-
Neoplasm Proteins / genetics
-
Pharmacogenetics / trends*
-
Polymorphism, Single Nucleotide / genetics
-
Precision Medicine / trends*
-
Trans-Activators / genetics
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Adaptor Proteins, Signal Transducing
-
Cell Adhesion Molecules
-
EYA4 protein, human
-
Neoplasm Proteins
-
PDZD2 protein, human
-
Trans-Activators
-
Tumor Necrosis Factor-alpha